Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Molecular Effects of Investigational AD Treatment Described
TOPLINE: Temtokibart, a novel monoclonal antibody, appears to achieve clinical improvements in moderate to severe atopic dermatitis (AD) by normalizing the skin barrier and increasing hydration, according to the results of a small, 16-week, phase 2a trial. METHODOLOGY: Interleukin (IL)-22…
English